Viridian Therapeutics, Inc.
Clinical trials sponsored by Viridian Therapeutics, Inc., explained in plain language.
-
New antibody shows promise for chronic thyroid eye disease in phase 3 trial
Disease control CompletedThis study tested an investigational drug called veligrotug in 188 people with chronic thyroid eye disease, a condition that causes eye bulging and discomfort. The drug works by blocking a specific receptor to reduce inflammation and tissue swelling behind the eyes. The main goal…
Phase: PHASE3 • Sponsor: Viridian Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 10:41 UTC
-
Second chance for TED patients: new drug shows promise for Non-Responders
Disease control CompletedThis study tested an investigational drug called VRDN-001 in 143 people with thyroid eye disease who did not respond to treatment in earlier studies. The drug aims to reduce eye inflammation and bulging by blocking a specific receptor. Participants received open-label VRDN-001, a…
Phase: PHASE3 • Sponsor: Viridian Therapeutics, Inc. • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
New drug shows promise for bulging eyes in thyroid disease
Disease control CompletedThis study tested a new drug called VRDN-001 in 231 people with thyroid eye disease, a condition that causes eye bulging and inflammation. The drug works by blocking a specific receptor to reduce swelling. The main goal was to check safety and how well people tolerate the treatme…
Phase: PHASE3 • Sponsor: Viridian Therapeutics, Inc. • Aim: Disease control
Last updated May 20, 2026 11:54 UTC